NovaBridge Biosciences (NBP) Stock

Healthcare · Biotechnology · Member of Other US Stocks

NovaBridge Biosciences (NBP) closed at USD 1.28 on 2026-10-14, a change of -72.4 % over the past year, with a market capitalization of USD 149.64M.

NovaBridge Biosciences recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

NovaBridge Biosciences key figures

Previous close

USD 1.28 (2026-10-14)

1-year change

-72.4 %

Market cap

USD 149.64M

Enterprise value

USD -36.75M

P/E ratio (trailing)

-1.84

P/E ratio (forward)

-1.22

EPS (trailing)

-0.70

EPS (forward)

-1.06

PEG ratio

n/a

Price to book

0.74

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

5.62

Employees

30

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About NovaBridge Biosciences

NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab and chemotherapy in first-line gastric cancer. The company also develops VIS-101, VEGF-A × ANG-2 bispecific biologics in Phase 2 clinical trial to treat wet age-related macular degeneration and other retinal diseases, including diabetic macular edema; ragistomag, which is in Phase 1clinical trial for multiple solid tumors. It has a licensing agreement with AskGene to develop and commercialize VIS-101; collaborations with Bristol Myers Squibb for the development of givastomig; and license and collaboration agreement with AbbVie Ireland Unlimited Company for the development and commercialization of lemzoparlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for NovaBridge Biosciences and compare it with other stocks.